## Metabolic Side Effects and Antipsychotic Selection **Key Point:** Metabolic syndrome (weight gain, hyperglycemia, dyslipidemia) is a major adverse effect of atypical antipsychotics, with olanzapine and clozapine carrying the highest risk. ### Metabolic Risk Profile of Atypical Antipsychotics | Antipsychotic | Weight Gain | Glucose Dysregulation | Lipid Elevation | Metabolic Risk | | --- | --- | --- | --- | --- | | **Aripiprazole** | Minimal | Minimal | Minimal | **Lowest** | | **Quetiapine** | Moderate | Moderate | Moderate | Moderate | | **Risperidone** | Moderate | Moderate | Moderate | Moderate | | **Olanzapine** | High | High | High | **Highest** | | **Clozapine** | High | High | High | **Highest** | | **Paliperidone** | Moderate–High | Moderate | Moderate | Moderate–High | **High-Yield:** Aripiprazole is a dopamine partial agonist (not a full antagonist) and has the lowest metabolic burden among all atypical antipsychotics. It is the preferred switch in patients with metabolic complications. ### Why Aripiprazole is Optimal Here 1. **Dopamine partial agonism:** Stabilizes dopamine neurotransmission without full blockade, reducing metabolic dysregulation. 2. **Minimal weight gain:** Often associated with weight loss or neutral effect. 3. **No glucose or lipid elevation:** Lowest risk among atypicals. 4. **Mood stabilization:** Effective for bipolar disorder maintenance. 5. **Reversibility:** Metabolic parameters often improve within weeks of switching. **Clinical Pearl:** Aripiprazole is the preferred antipsychotic in patients with pre-existing metabolic syndrome, diabetes, or significant weight gain on other agents. It can be used in both schizophrenia and bipolar disorder. **Mnemonic:** **AAAA** = **Aripiprazole = Atypical with Absent Adverse metabolic effects**
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.